What is AZN's market cap?

$289.79B, based on the Nov 5 close of $186.85.

What is AZN's P/E ratio?

130.5× trailing-twelve-month earnings of $2.22B.

Does AstraZeneca pay a dividend?

Yes. The latest regular dividend was $0.795 per share (ex-date Aug 7), an annualised yield of 0.85%.

NYSE · AZN

AstraZeneca PLC (AZN)

$186.85−1.14%

Close Nov 5, 2026 · split-adjusted

Nov 5, 2026$186.85▲ 15.13% in range

Nov 5, 2025Low $155.62 · High $209.48Nov 5, 2026

What changed · written from our data

As of Nov 5, 2026

AstraZeneca closed at $186.85 on Nov 5, down 1.14%, 10.8% below its 52-week closing high. Volume of 4.8M shares was 1.46× its 20-day average (above normal).

Split-adjusted performance: +16.7% over one month, +2.4% over six months, +13.9% over one year.

In the quarter ended Jun 30, 2016, revenue was $5.60B, down 11.2% from a year earlier, with a net margin of -0.1%.

Short interest was 3.3M shares at the Oct 15 settlement, up 25.4% from the prior report (1.1 days to cover).

Market cap$289.79B1.55B shares

Revenue · quarter$5.60B−11.2% YoY

Diluted EPS$0.00−100.0% YoY

P/E · TTM130.5×P/S 12.0×

Net margin-0.1%Gross 79.4%

Dividend yield0.85%$0.795 last paid

52-week range155.62 – 209.48−10.8% from high

Volume4.8M1.46× 20-day avg

Volatility · 60d27.6%Annualised

Short % of float—1.1 days to cover

Net cash-$22.08BCash $5.74B

Next earnings—Not scheduled

Split-adjusted performance

1W +7.1%1M +16.7%3M +15.8%6M +2.4%YTD +1.6%1Y +13.9%3Y +47.8%5Y +50.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within industry

Not enough peers to rank

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Short interest

Details →

Shares short3.3M+25.4% vs prior

Days to cover1.1Settled Oct 15

% of float—

Short vol. 10d55.2%of daily volume

News about AstraZeneca

All news →

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales GrowthZacks Investment Research · 6d ago▲ Positive Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib)GlobeNewswire Inc. · Oct 26, 2026▲ Positive AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA NephropathyZacks Investment Research · Oct 22, 2026▲ Positive The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema OncologyZacks Investment Research · Oct 19, 2026▲ Positive Astrazeneca (AZN) Rises Higher Than Market: Key FactsZacks Investment Research · Oct 15, 2026Neutral

Quick answers

What does AstraZeneca do?: A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%).
What is AZN's market cap?: $289.79B, based on the Nov 5 close of $186.85.
What is AZN's P/E ratio?: 130.5× trailing-twelve-month earnings of $2.22B.
Does AstraZeneca pay a dividend?: Yes. The latest regular dividend was $0.795 per share (ex-date Aug 7), an annualised yield of 0.85%.

About AstraZeneca

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

96,100 employeesListed Oct 23, 2009astrazeneca.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology